Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi Girds For Rising Yuan, Weakening U.S. Dollar

This article was originally published in PharmAsia News

Executive Summary

WuXi PharmTech believes it is prepared, unlike some of its Chinese outsourcing competitors, for the expected appreciation of the Chinese yuan, which could affect business from U.S. firms as the dollar weakens and it becomes more expensive to outsource to China

You may also be interested in...



WuXi PharmaTech Launches Talent Flow with Acquired U.S. Firm AppTec

BEIJING - WuXi PharmaTech, one of China's leading contract research organizations, is moving rapidly to integrate operations and foster a talent flow with its recently acquired American biologics outfit AppTec Laboratory Services

WuXi PharmaTech Launches Talent Flow with Acquired U.S. Firm AppTec

BEIJING - WuXi PharmaTech, one of China's leading contract research organizations, is moving rapidly to integrate operations and foster a talent flow with its recently acquired American biologics outfit AppTec Laboratory Services

Shanghai ChemPartner CEO Michael Hui On Finding A Niche In China Amidst Increasing Foreign Competition: An Interview With PharmAsia News (Part 2 of 2)

Shanghai ChemPartner was set up in 2003 at Shanghai's Zhangjiang Hi-Tech Park, and today it is one of the leading R&D outsourcing providers in China. PharmAsia News recently visited company headquarters to meet Michael Hui, CEO of ChemPartner - as well as sister company ChemExplorer, and their holding company ShangPharma - to discuss the company's recent deal with private equity investment firm TPG, as well as handling increased competition from foreign firms moving into China.

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel